No Longer Incurable

The Antidote Exists

Mara: “From now on, we will no longer say that Ebola is incurable,” virologist Jean-Jacques Muyembe told reporters. He added, “These advances will help save thousands of lives.”

Eli: Yet a listener asks where Ebola comes from, and why after decades we still do not have an antidote.

Mara: Here is the twist: an antidote already exists. In December 2019, American regulators approved the Ervebo vaccine.

Eli: Then in late 2020, the agency approved two therapies for Zaire ebolavirus, Inmazeb and Ebanga. How do those therapies actually work?

Mara: They are monoclonal antibodies—lab-made immune proteins designed to clamp onto one specific protein on a virus like a tailored lock-and-key. They neutralize virus particles before cells get invaded.

Eli: Wait, when patients received Ebanga early, mortality plunged to 11 percent. With Inmazeb, only 6 percent died. That completely flips what people expect.

Mara: To trace how we got here, start in 1976. Outbreaks emerged simultaneously across Central Africa.

Eli: A flare-up hit Nzara, in what is now South Sudan, driven by Sudan virus.

Mara: That outbreak sickened 284 people. It killed 151.

Eli: At the very same time, cases erupted in Yambuku, Zaire. A 44-year-old school headmaster named Mabalo Lokela fell ill after traveling near the Ebola River.

Mara: That river ended up lending its name to the unknown pathogen.

Eli: Doctor Ngoy Mushola tracked patients with burning fevers, bloody diarrhea, and vomiting blood. On average, victims died in three days.

Mara: Yambuku saw 318 infections. The illness carried an 88 percent case-fatality rate—the proportion of people diagnosed with a disease who die from it.

Eli: That horrifying toll defined the virus for a generation. If the virus was identified in 1976 and lives in Central African forests, where does it hide between human outbreaks?

The Forest Reservoir

Mara: In tropical forests, Ebola persists in a sylvatic cycle. That is the quiet natural cycle of a pathogen circulating among wild animals without human involvement.

Eli: It periodically spills over into secondary victims. We see severe, often fatal infections in chimpanzees, gorillas, and forest duikers.

Mara: People run into danger when handling bushmeat. Direct contact with blood or organs of those infected animals introduces the pathogen into our communities.

Eli: Unlike airborne bugs like flu, Ebola transmission among humans is relatively inefficient. The pathogen requires a liquid vehicle like blood or saliva to persist, so infection demands physical contact.

Mara: Right, airborne spread between humans or other primates has never been documented in nature or in labs.

Eli: Even so, historical outbreaks saw devastating mortality rates. Across all recorded outbreaks, that fatality rate averages roughly 50 percent.

Mara: That leaves the puzzle: where does it hide between outbreaks? The World Health Organization views fruit bats as the reservoir host—an animal species that permanently sustains a virus in nature without succumbing to fatal illness.

Eli: Fruit bats are thought to be the natural hosts.

Mara: For good reason. A 2005 Nature paper by Eric Leroy detailed tests during 2003 Gabon outbreaks. Researchers detected viral RNA in 13 fruit bats. Ebola antibodies also appeared in other bat specimens without the animals dying.

Eli: Still, Kenyan wildlife biologist Paul Webala stresses that antibodies only show exposure. They do not prove an animal is the source, and he argues conclusive evidence is missing.

Mara: Because having antibodies just means an animal survived an encounter with the virus at some point.

Eli: Exactly. And consider recent field testing: scientists examined over 1,000 bats during outbreaks in the Democratic Republic of the Congo and found zero viral RNA.

Mara: I concede that gap. Nobody has ever isolated live, replicating virus from wild bats, leaving the true reservoir unconfirmed.

Eli: A 2023 study in Biology Letters titled its findings plainly: "Robust evidence for bats as reservoir hosts is lacking for most African virus studies." If scientists knew the virus and its forest ecology decades ago, why did it take nearly forty years to develop an approved drug?

The Decades of Delay

Mara: From its discovery in 1976 up to the West Africa crisis, cases were sporadic. The virus infected roughly twenty-four hundred people in that entire stretch.

Eli: Only twenty-four hundred cases across all those decades.

Mara: Private drugmakers will not fund expensive clinical research for an illness that affects a few hundred people a year.

Eli: That market neglect was real, but the laboratory biology created massive bottlenecks too. Handling live virus demands Biosafety Level 4.

Mara: Because of how dangerous it is to handle?

Eli: It is the maximum biological containment level, where researchers work inside airtight positive-pressure suits with dedicated air supplies. Biodefense researcher Nancy Sullivan pointed out that those cumbersome suits make Ebola research take twice as long as malaria studies.

Mara: And you cannot run a Phase 3 efficacy trial when there are no active cases in the community. Even public sector momentum faltered after federal research budgets crested in 2004.

Eli: Right when experimental candidates needed steady backing to advance.

Mara: Francis Collins, who led the National Institutes of Health, later said that without slipping funds, "we would have been a year or two ahead of where we are, which would have made all the difference."

Eli: Funding alone could not fix the study design problem, though. Evaluating candidate therapies requires a randomized controlled trial.

Mara: A study where patients are randomly assigned to either receive the test treatment or standard care to verify efficacy.

Eli: Exactly. When containment succeeds, the patient pool vanishes midstream.

Mara: The trial literally runs out of people.

Eli: That stalled the experimental antibody cocktail ZMapp. Researchers planned to enroll two hundred participants.

Mara: Right as the outbreak started fading.

Eli: Enrollment closed after 72 patients, leaving the data statistically inconclusive.

Mara: What finally broke that forty-year logjam when West Africa was overwhelmed in 2014?

Breakthrough in the Crisis

Eli: The sheer devastation in West Africa pushed the World Health Organization to sound an international alarm. More than 28,000 infections were logged across that outbreak. Over 11,000 people lost their lives.

Mara: That catastrophe shattered the commercial deadlock. Global donors stepped in, guaranteeing drug companies that approved shots would have guaranteed buyers.

Eli: Gavi offered advance purchase deals for candidate vaccines. In 2016, the pharmaceutical firm MSD agreed to terms. They established an emergency stockpile of 300,000 doses.

Mara: Researchers tested that vaccine in Guinea through ring vaccination. That meant vaccinating all direct contacts around an infected individual to build a protective ring that halts transmission.

Eli: In that trial among thousands of contacts, the delayed-vaccination group recorded 16 infections.

Mara: Meanwhile, the group receiving immediate vaccination had zero cases. Its calculated protection reached 100 percent.

Eli: Zero infections. In the midst of an uncontrolled outbreak, that is a stunning outcome.

Mara: MSD completed the vaccine process in five years. That cut normal development time in half.

Eli: At the same time, therapies returned to those monoclonal antibodies we talked about earlier. Researchers derived the drug Ebanga from an antibody of someone who survived the 1995 Kikwit outbreak in the Democratic Republic of the Congo.

Mara: Ebanga relies on that lone survivor antibody. Inmazeb combines three. Both lock onto the glycoprotein—the spike protein sticking out from the viral surface that lets it invade human cells.

Eli: When the landmark PALM trial compared them head-to-head, the turning point finally arrived.

Mara: On August 9, 2019, independent monitors stopped the study early. Data from 499 patients revealed that the antibody treatments dramatically outperformed earlier options.

Eli: The earlier candidates fell behind. Patients receiving ZMapp early still saw mortality around 24 percent. For remdesivir, death rates reached about 33 percent.

Mara: Across all patients, Ebanga brought mortality down to 34 percent. Inmazeb pushed it further down, to 29 percent.

Eli: Those results transformed the standard of care. But with proven cures and vaccines now licensed, does that mean the Ebola threat is permanently solved?

The Strain Gap

Mara: Not by a long shot. Every approved antibody therapy and our single licensed vaccine focus entirely on one species: Zaire ebolavirus.

Eli: Which means if someone contracts Sudan virus or Bundibugyo virus, those drugs offer no documented help?

Mara: None at all. That specificity leaves patients completely unprotected when other filovirus species strike.

Eli: We are watching that gap play out right now. On May 17, 2026, the World Health Organization named the Bundibugyo outbreak in Uganda and the DRC an international public health emergency.

Mara: A global crisis with zero approved therapeutics ready on pharmacy shelves.

Eli: Not one. By late July 2026, confirmed cases in the DRC alone climbed to 2,905.

Mara: Even for Zaire, getting vaccines to patients depends on the ultra-cold chain. That is an unbroken transport system keeping supplies below minus 60 degrees Celsius using specialized freezers and dry ice.

Eli: Maintaining deep freeze conditions like that is tough enough anywhere.

Mara: And the licensed vaccine demands storage below minus 70 degrees Celsius. In rural areas where even regional capitals suffer blackouts, that creates a punishing obstacle.

Eli: Yet Jean-Jacques Muyembe proved his point when he declared Ebola was no longer incurable. After that response wrapped up in 2020, WHO head Tedros Adhanom Ghebreyesus called it “a victory for science.”

Mara: It truly saved lives.

Eli: It broke the biological deadlock on Zaire. But the next hurdle is building that same defense for other species before the next forest spillover takes off.

Mara: So the listener's premise is solved: we do have antidotes now. But until those treatments cover every filovirus, the job remains unfinished.

Eli: Look into ring vaccination.

Mara: And follow health; we have more stories there so you stay informed as outbreak responses evolve.

Eli: I'm Eli.

Mara: And I'm Mara. Thanks for listening. We'll catch you next time on Angle.